Shares of Qiagen (NYSE:QGEN – Get Rating) have been assigned an average recommendation of “Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $53.11.
Separately, Zacks Investment Research upgraded Qiagen from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Friday, April 22nd.
Institutional investors and hedge funds have recently made changes to their positions in the company. Morgan Stanley increased its holdings in Qiagen by 61.9% in the second quarter. Morgan Stanley now owns 917,158 shares of the company’s stock valued at $44,372,000 after purchasing an additional 350,613 shares during the period. BlackRock Inc. grew its stake in shares of Qiagen by 25.6% in the 3rd quarter. BlackRock Inc. now owns 6,056,924 shares of the company’s stock valued at $313,022,000 after buying an additional 1,233,483 shares during the period. Alliancebernstein L.P. lifted its position in Qiagen by 0.9% in the 3rd quarter. Alliancebernstein L.P. now owns 165,786 shares of the company’s stock valued at $8,568,000 after acquiring an additional 1,446 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its position in Qiagen by 75.7% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 650 shares of the company’s stock valued at $34,000 after acquiring an additional 280 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Qiagen by 13.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 43,900 shares of the company’s stock valued at $2,269,000 after acquiring an additional 5,300 shares in the last quarter. Institutional investors own 55.85% of the company’s stock.
Qiagen (NYSE:QGEN – Get Rating) last released its earnings results on Tuesday, April 26th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.71 by $0.09. The company had revenue of $628.39 million during the quarter, compared to analysts’ expectations of $589.95 million. Qiagen had a return on equity of 20.71% and a net margin of 26.61%. During the same period last year, the firm earned $0.66 EPS. On average, equities analysts expect that Qiagen will post 2.52 earnings per share for the current fiscal year.
About Qiagen (Get Rating)
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
- Get a free copy of the StockNews.com research report on Qiagen (QGEN)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.